Biotech Reports 'Eye-Catching, Topline Results' from RSV Vaccine Study
Source: Streetwise Reports  (6/19/19)
The data and how the asset stacks up to others were covered in a ROTH Capital Partners report. More >

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study
Source: Streetwise Reports  (6/19/19)
The highlights of the results were presented in an H.C. Wainwright & Co. report. More >

Biopharma Advances Dose Escalation Trial in Alcoholic Hepatitis
Source: Streetwise Reports  (6/19/19)
The company received approval to proceed with the next and final dose level. More >

Interim Results Put Biopharma with Tenbagger Potential 'Back on the Map'
Source: Streetwise Reports  (6/11/19)
A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report. More >

Biotech to Present Alzheimer's Disease Therapeutic at Keystone Symposium
Source: Streetwise Reports  (6/8/19)
The focus will be the Canadian company's lead monoclonal antibody candidate. More >

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic
Source: Streetwise Reports  (6/5/19)
An explanation of the categorization and its implications are provided in a Paradigm Capital report. More >

Coverage Initiated on Biotech Whose Therapies 'Can Compete with CAR-Ts'
Source: Streetwise Reports  (6/5/19)
The reasons for the Buy rating on the U.K. firm are delineated in a ROTH Capital Partners report. More >

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'
Source: Streetwise Reports  (5/28/19)
The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. More >

Biotech Identifies Antibodies for Toxic Tau in Alzheimer's Disease
Source: Streetwise Reports  (5/28/19)
The Canadian company's approach to this indication is now twofold. More >

California-Based Biopharma Signs Licensing Deal for Acquired Asset
Source: Streetwise Reports  (5/25/19)
The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report. More >

Oncology Vaccine Developer's Lead Programs 'On Track or Better'
Source: Streetwise Reports  (5/22/19)
The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. More >

Immuno-oncology Firm to Co-Develop Companion Diagnostic for Cervical Dysplasia
Source: Streetwise Reports  (5/22/19)
The partnership news and upcoming data readouts are reviewed in an H.C. Wainwright & Co. report. More >

U.S. Biopharma's 'Biggest Stock Moving Event' Imminent
Source: Streetwise Reports  (5/22/19)
With study results from this company due out shortly, an analysis of the possible outcomes was provided in a ROTH Capital Partners report. More >

Cancer Fighter Sesen Bio Leaps 13% on FDA Decision
Source: Streetwise Reports  (5/21/19)
Shares of this biotech stock were up significantly at the close of trading on Tuesday, May 21, attributed to the announcement of some good news from the FDA. More >

Harrow Comes Out of Allergan Lawsuit Unscathed
Source: Daniel Carlson for Streetwise Reports  (5/17/19)
Sector expert Daniel Carlson offers his take on the recent jury decision, calling it "very positive." More >

Why Did ImmunoGen Plummet 32%?
Source: Streetwise Reports  (5/16/19)
This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. More >

FDA Approval of Antibiotic for Bacterial Pneumonia Expected in Late Summer
Source: Streetwise Reports  (5/15/19)
An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report. More >

Biopharma Releases Preliminary Data from Alcoholic Hepatitis Study
Source: Streetwise Reports  (5/10/19)
The results compare favorably to those of the historical control group. More >

Trial Milestone Reached; U.K.-Based Biopharma Gets $15 Million
Source: Streetwise Reports  (5/8/19)
The first patient has been treated in the second cohort of a Phase 2 study of a gene therapy targeting Parkinson's disease, explained an H.C. Wainwright & Co. report. More >

Price Target Raised on Biopharma Ahead of Leukemia Trial Update
Source: Streetwise Reports  (5/8/19)
The expected data and their implications were addressed in a ROTH Capital Partners report. More >

'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial
Source: Streetwise Reports  (5/1/19)
A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report. More >

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech
Source: Streetwise Reports  (5/1/19)
Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. More >

Firm's AR E-Commerce Solutions to Be Marketed, Sold to Dispensaries
Source: Streetwise Reports  (4/29/19)
With the signing of a reseller agreement, the tech firm continues to penetrate Canada's burgeoning legal cannabis industry. More >

'Undervalued' Biopharma Features Robust Pipeline, Future Upside
Source: Streetwise Reports  (4/24/19)
The case for investing in this company was made in an H.C. Wainwright & Co. report. More >

California Gold Mining Full Speed Ahead in Hemp
Source: Peter Epstein for Streetwise Reports  (4/18/19)
Peter Epstein of Epstein Research provides an update on a mining exploration company that is diversifying into the hemp market. More >